2.81
-0.51(-15.36%)
Currency In USD
| Previous Close | 3.32 |
| Open | 3.18 |
| Day High | 3.2 |
| Day Low | 2.72 |
| 52-Week High | 19.3 |
| 52-Week Low | 1.08 |
| Volume | 721,346 |
| Average Volume | 3.86M |
| Market Cap | 17.6M |
| PE | -0.23 |
| EPS | -12.07 |
| Moving Average 50 Days | 2.94 |
| Moving Average 200 Days | 2.31 |
| Change | -0.51 |
If you invested $1000 in Sonnet BioTherapeutics Holdings, Inc. (SONN) 10 years ago, it would be worth $0 as of August 02, 2025 at a share price of $2.81. Whereas If you bought $1000 worth of Sonnet BioTherapeutics Holdings, Inc. (SONN) shares 5 years ago, it would be worth $0.16 as of August 02, 2025 at a share price of $2.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
GlobeNewswire Inc.
Jul 14, 2025 10:00 AM GMT
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasuryPRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced t
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire Inc.
May 01, 2025 1:00 PM GMT
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announc
Sonnet Releases Virtual Investor "What This Means" Segment
GlobeNewswire Inc.
Apr 16, 2025 1:10 PM GMT
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NE